Immunology Preclinical Deal Benchmarks (2026)

Median upfront of $72M with total deal values reaching $1.6B.

Median Upfront

$72M

Total Deal Value

$1.0B

Royalty Range

5.8%–11.5%

Territory Multiplier

Understanding Immunology Deal Benchmarks at Preclinical

Preclinical Immunology licensing deals command a median upfront payment of $72M, with values ranging from $26M at the low end to $123M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the immunology therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.

Total deal values — including milestones for development, regulatory, and commercial achievements — range from $468M to $1.6B, with a median of $1.0B. Royalty rates for immunology assets at this stage typically fall between 5.8% and 11.5% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.

The Global territory applies a 1x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating global rights should calibrate upfront expectations and milestone structures accordingly.

PRO

Full Market Analysis

Detailed deal economics, territory impact analysis, and royalty structure breakdown.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Full Benchmark Data

PRO

Full Benchmark Table

Low, median, and high ranges for upfront payments, total deal values, and royalty rates.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Comparable Deals

Year	Licensor	Licensee	Upfront	Total Value	Deal Type
2024	Regeneron	Sanofi	$0M	$13.0B	collaboration
2023	Pharming Group	CSPC Pharmaceutical	$15M	$180M	licensing
2023	Almirall	AbbVie	$50M	$660M	licensing
2024	Connect Biopharma	Astellas Pharma	$25M	$350M	licensing
2021	Alexion Pharmaceuticals	AstraZeneca	$39.0B	$39.0B	acquisition
2024	Alnylam Pharmaceuticals	Roche	$310M	$2.5B	collaboration
2024	Apellis Pharmaceuticals	N/A (standalone)	$0M	$800M	licensing
2020	Principia Biopharma	Sanofi	$3.7B	$3.7B	acquisition
2024	Numab Therapeutics	AstraZeneca	$50M	$1.2B	licensing
2023	Kymera Therapeutics	Sanofi	$150M	$2.0B	collaboration

PRO

See All Comparable Deals

View 10 comparable Immunology transactions with upfront payments, total values, and deal structures.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Frequently Asked Questions

What is the average upfront payment for Preclinical Immunology deals?

The median upfront payment for Preclinical Immunology licensing deals is $72M, based on our analysis of comparable transactions. Values range from $26M for early-stage or less differentiated assets up to $123M for premium programs with strong clinical data or first-in-class mechanisms.

How does Global territory affect Immunology deal value?

Global rights carry a 1x multiplier relative to base deal economics. This means global immunology deals are valued at a discount compared to single-country rights, reflecting the combined market opportunity, regulatory pathway, and competitive dynamics of the territory.

What royalty rates are typical for Preclinical Immunology licensing?

Royalty rates for Preclinical immunology assets typically range from 5.8% to 11.5% of net sales. The exact rate depends on the licensor's contribution (IP, clinical data, manufacturing), deal structure (exclusive vs. co-exclusive), and the licensee's commercialization investment. Higher royalties often correspond to lower upfront payments, and vice versa.

PRO

More Expert Insights

Territory impact analysis, royalty negotiation strategies, and deal structure guidance.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Related Benchmarks

$163M upfront

Immunology · Phase 1 · Global

$547M upfront

Immunology · Phase 2 · Global

$901M upfront

Immunology · Phase 3 · Global

$3.4B upfront

Immunology · Approved · Global

$32M upfront

Oncology · Preclinical · Global

$32M upfront

Neurology/CNS · Preclinical · Global

$77M upfront

Metabolic/Obesity · Preclinical · Global

$39M upfront

Immunology · Preclinical · US Only

Explore More

All Immunology Deals

View full therapeutic area benchmarks

Licensing Benchmarks Guide

2026 data from 1,900+ deals

Royalty Rate Benchmarks

Negotiation strategies by phase & modality

Run Custom Analysis

Pre-filled with Immunology · Preclinical

Run Your Own Benchmark

These benchmarks are starting points. Get a customized valuation for your specific asset, indication, and deal structure.

Open Deal Calculator

Cite This Data

APA

Ambrosia Ventures. (2026). Immunology Preclinical Deal Benchmarks (2026). Retrieved from https://calculator.ambrosiaventures.co/data/immunology-preclinical-deals-global

HTML

<a href="https://calculator.ambrosiaventures.co/data/immunology-preclinical-deals-global">Immunology Preclinical Deal Benchmarks (2026)</a> — Ambrosia Ventures (2026)

Embed Chart

Data sourced from 1,900+ verified biopharma transactions. Updated monthly.

Metric	Low	Median	High
Upfront Payment	$26M	$72M	$123M
Total Deal Value	$468M	$1.0B	$1.6B
Royalty Rate	5.8%	—	11.5%